HCV Treatment
AASLD 2014: Sofosbuvir/ Ledipasvir + Ribavirin Cures Most Post-Transplant HCV Recurrence
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 25 November 2014 00:00
- Written by Liz Highleyman
An interferon-free regimen of sofosbuvir plus ledipasvir (Harvoni) taken with ribavirin for 12 or 24 weeks led to sustained virological response in nearly all HCV genotype 1patients with fibrosis or less-advanced liver cirrhosis, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston. Response rates fell for people with more severe cirrhosis and signs of liver decompensation, but still a majority were cured.
AASLD 2014: Sofosbuvir + Simeprevir Shows Good Results in Real-World Use
- Details
- Category: Approved HCV Drugs
- Published on Friday, 21 November 2014 00:00
- Written by Liz Highleyman
Regimens containing sofosbuvir (Sovaldi) -- including sofosbuvir plus simeprevir (Olysio) -- work well for people with hepatitis C genotype 1 in real-world use, which to date has included some of the patients most urgently in need of treatment at the dawn of the interferon-free era, according to a pair of presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston. Sofosbuvir plus ribavirin alone is highly effective for people with genotype 2.
Harvoni Coformulation Approved in Europe for Hepatitis C Genotypes 1 & 4
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 19 November 2014 00:00
- Written by Gilead Sciences
Gilead Sciences' Harvoni, a once-daily fixed-dose coformulation containing the nucleotide HCV polymerase inhibitor sofosbuvir and the NS5A replication complex inhibitor ledipasvir, has been approved by the European Commission for the treatment of people with hepatitis C genotypes 1 and 4, the company announced this week.
AASLD 2014: AbbVie 3D Regimen and Sofosbuvir/ Ribavirin Show High Cure Rates for HIV/HCV Coinfection
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 19 November 2014 00:00
- Written by Liz Highleyman
AbbVie's 3D regimen (paritaprevir/ombitasvir/ritonavir plus dasabuvir) with ribavirin for 12 weeks and Gilead Science's sofosbuvir (Sovaldi) plus ribavirin for 24 weeks both produced good sustained virological response rates for most patients with HIV and hepatitis C virus (HCV) coinfection, according to studies presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston.
AASLD 2014: Daclatasvir + Sofosbuvir Demonstrates Good Cure Rate for HCV Genotype 3 Patients
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 19 November 2014 00:00
- Written by Liz Highleyman
An all-oral combination of daclatasvir (Daklinza) plus sofosbuvir (Sovaldi) taken for 12 weeks produced sustained virological response rates of 90% for previously untreated patients and 86% for prior non-responders with hepatitis C virus genotype 3 in the Phase 3 ALLY-3 trial, researchers reported last week at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston. This regimen did not work as well, however, for people with liver cirrhosis.
More Articles...
- AASLD 2014: Sofosbuvir + GS-5816 for 12 Weeks Shows High Cure Rates, 8 Weeks Less Effective
- AASLD 2014: Grazoprevir/ Elbasvir Combo Shows High Cure Rates, Including Cirrhotics and Coinfected
- AASLD 2014: Sofosbuvir/ Ledipasvir + Ribavirin Highly Effective for People with Decompensated Cirrhosis
- AASLD 2014: Sofosbuvir/Ledipasvir and AbbVie 2D Cure Most People with HCV Genotype 4
Web Design and Development by